DocWire News Editors

DocwireNews

According to a study presented at the European Society for Medical Oncology Virtual Congress 2020, pembrolizumab plus AUTO3, an investigational CD19/CD22 dual targeting chimeric antigen receptor (CAR) T-cell therapy, was well tolerated in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).The dose-escalation portion of the single-arm, multicenter, phase I/II ALEXANDER study examined three dose levels of AUTO3: 50&times;106, 150&times;106,&nbsp;and 450&times;106&nbsp;CAR T-cells. AUTO3 was dosed alone or in combination with pembrolizumab 200 mg every three weeks 14 days after AUTO3 infusion or pembrolizumab 200 mg on day one after AUTO3 infusion.At data cutoff (August 3, 2020), 35 patients (median age, 59 years; range, 28-83 years; 65.7% were men) with DLBCL (n=25), follicular lymphoma (n=7), or marginal zone lymphoma (n=1) were evaluable for safety outcomes. Patients received a median of three prior therapies (range, 1-10 therapies).AUTO3 was well tolerated, according to the manufacturer, with no grade &ge;3 cytokine release syndrome (CRS) with primary infusion; 22.9% of patients experienced grade 1 CRS, and five received tocilizumab to resolve their symptoms. There were three cases of neurotoxicity, two (5.7%) of which were grade &ge;3.&nbsp;Among the 20 patients treated at a dose of &ge;150&times;106&nbsp;cells (recommended phase II dose) with pre-conditioning pembrolizumab on day &ndash;1, one patient experienced grade &ge;3 neurotoxicity. One patient died due to disease progression and multiorgan failure.&nbsp;No patients who achieved complete response (CR) experienced neurotoxicity. All cases of neurotoxicity were atypical in nature and seen in a setting with disease progression and confounding factors, according to the manufacturers.The cohort receiving a dose of &ge;150&times;106&nbsp;cells and pre-conditioning pembrolizumab on day &ndash;1 had an objective response rate (ORR) of 71% and CR rate of 64%.&nbsp;Across all dose levels studied, the ORR was 68% and CR rate was 54%. Seven patients who received the recommended phase II dose (150&times;106&nbsp;to 450&times;106&nbsp;CAR T-cells plus pembrolizumab on day one) and achieved complete remission remained in remission at a median follow-up of six months (range, 1-24 months).

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

Investigational Dual Targeting CAR T-Cell Therapy Plus Pembrolizumab Has Tolerable Safety Profile

Oncology

According to a study presented at the European Society for Medical Oncology Virtual Congress 2020, pembrolizumab plus AUTO3, an investigational CD19/CD22 dual targeting ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe